Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
BIOQUANT develops analysis software and imaging systems for musculoskeletal tissues and cell culture systems. Software demonstrations available via Zoom. Specially designed tools simplify analysis of skeletal phenotype, skeletal muscle phenotype, bone marrow adiposity, implant osseointegration, fracture repair, cancer metastasis, and much more. In 2020, we are excited to announce support for confocal microscopy and lightsheet image data. With this multi-Z and multi-channel image data, BIOQUANT now supports a range of new analysis tasks like cortical bone innervation, analysis of protein distribution in trabecular bone.
BRUKER BioSpin GmbH
Bruker-MicroCT develops and manufactures micro and nano-CT scanners both in vivo and ex vivo, with the highest resolution and imaging performance over both categories. Bruker SkyScan scanners have been essential tools for bone researchers for more than 2 decades. In-vivo imaging with physiological monitoring is within proven safe dose limits. Scanners are supplied with comprehensive analysis software featuring high speed GPU reconstruction, versatile volume of interest selection tools including trabecular-cortical separation, calibrated BMD/TMD, comprehensive 3d and 2d parameters (ASBMR-compliant) and customisable batch operations. In-depth bone research and morphometry support is provided. Bruker-MicroCT customers are closely supported by 66 distributors worldwide.
European Calcified Tissue Society
The European Calcified Tissue Society is a medical society bringing together researchers and clinicians working in the field of calcified tissues and related fields. For over 50 years, ECTS is dedicated to pursuing excellence in research, best practices and in providing education to all those interested in the field. While ECTS is founded in Europe, we engage globally with all stakeholders in the field.
Membership is open to anyone working in the field at whatever stage in their career. Come and meet us in Marseille at our booth.
Visit our website www.ectsoc.org and follow up on twitter @ECTS_soc | @ECTS_science
Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Elsevier journals in the musculoskeletal field provide a stage for global research collaboration. Our journals, broad ranging in scope, serve the research needs of educators, researchers and students forging developments and discoveries with significant real-world scientific impacts. Take advantage of a new offer for ECTS Members and receive a 20% discount on the article publication charge (APC) when you publish your paper in Bone Reports.
Fresenius Kabi France
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.
Our products and services are used to help care for critically and chronically ill patients. Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products.
In the field of nephrology, Fresenius Kabi offers specific products to better control the kidney function of patients with chronic kidney disease.
Gedeon Richter Plc., Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China and Latin America. Richter’s consolidated sales were approximately EUR 1.56 billion in 2019, reaching a market capitalisation of EUR 4.1 billion. Richter’s product portfolio covers many important therapeutic areas, including Women’s Healthcare and Central Nervous System. Richter is also active in biologic product development, and committed to bringing biosimilar products to global markets.
International Conference on Children’s Bone Health (ICCBH)
3-6 July 2021, Dublin, Ireland | Abstract deadline: 15 February 2021
ICCBH is your opportunity to hear about and discuss the newest developments in our understanding of paediatric bone health and disease.
We invite anyone with an interest in bone metabolism and bone mass in children, adolescents and young adults to attend. The biennial ICCBH conference is attended by over 600 delegates from across the globe, making it truly multinational and multidisciplinary – a unique networking opportunity.
In addition for 2021, ICCBH Bone School takes place in Dublin 30 June to 2 July – a 3-day educational course on paediatric bone health and rare bone diseases.
Come and participate in a lively interactive meeting with the leaders in the field!
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization.
Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization.
We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.
International Federation of Musculoskeletal Research Society (IFMRS)
The IFMRS is an international, not-for profit federation of musculoskeletal research societies whose purpose is to promote excellence in the field of
musculoskeletal science, in order to improve the prevention and treatment of all musculoskeletal (MSK) conditions worldwide.
They do this by collaborating with, and fostering collaboration between, local, regional and international organizations to share information and resources,
raise public awareness, influence policy and provide education.
They bring together major musculoskeletal research societies from across the world, with a combined membership of over 15,000, and working across the full
spectrum of MSK conditions, from rare diseases to osteoporosis and osteoarthritis.
Kyowa Kirin commits to innovative drug discovery driven by state-of-the-art technologies. The company focuses on creating new values in the four therapeutic areas: nephrology, oncology, immunology/allergy and neurology. Under the Kyowa Kirin brand, the employees from 36 group companies across North America, EMEA and Asia/Oceania unite to champion the interests of patients and their caregivers in discovering solutions wherever there are unmet medical needs.
Nestle Nutrition a division of Nestlé Enterprise S.A
The Nestlé Nutrition Institute (NNI), as a non for profit association in Switzerland, shares leading science based information and education with practicing health professionals in all parts of the world. NNI is committed to foster the highest levels of discussion within scientific community and build nutrition knowledge globally. All NNI exclusive resources are available at http://www.nestlenutrition-institute.org.
Scanco Medical AG (www.scanco.ch), established 1988, is a global provider of microCT, VivaCT and XtremeCT (HR-pQCT) systems as well as scan/analysis services. Systems are bundled with sophisticated, easy to use, analysis and visualization software as well as automatic specimen changers (specimen systems only). Scanco Medical is the only company which offers a fully integrated optional Finite Element Analysis Software package with its systems. Optional hardware include a mechanical testing stage and GPU reconstruction engine. Scanco Medical is also pleased to announce the availability of complete Windows® based systems beginning 2021. We wish all ECTS participants the best for the future.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.
Stratec Medizintechnik is the world’s most successful producer of pQCT-based bone densitometry scanners. Results are presented in real density units (g/cm³). Additionally, geometrical properties of bone can be analysed which allow the estimation of mechanical properties. The combined analysis of muscle and bone allows differentiation of disuse osteopenia from true osteoporosis.
The sister company Novotec Medical is manufacturer of Galileo vibration training devices for muscle stimulation and of Leonardo motion analysis systems (mechanography). The side alternating technology employs a natural movement similar to human gait. Improvement of muscle function, treatment of back pain and immobility are typical fields of application.
UCB Biopharma SRL
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives Follow us on Twitter:@UCB_news.